Latest California Healthline Stories
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
KHN’s ‘What the Health?’: News You Might Have Missed
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare’s coverage decision for the controversial Alzheimer’s disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Doctors Trying to Prescribe Abortion Pills Across State Lines Stymied by Legislation
Some doctors are getting licensed in multiple states so they can use telemedicine and mail-order pharmacies to provide medication abortions to more women. At the same time, states are cracking down on telemedicine abortions, blunting the efforts of out-of-state doctors.
Pfizer CEO Pushes Yearly Shots for Covid. Not So Fast, Experts Say.
A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
KHN’s ‘What the Health?’: Congress Shelves Covid Funding for Now
The Biden administration’s request for billions more in funding to fight covid-19 hit a snag on Capitol Hill this week, as Democrats objected to Republican demands that money allocated to states but not yet spent be reclaimed. Meanwhile, the big annual spending bill about to cross the finish line addresses other health policy changes, such as giving the FDA authority to regulate “synthetic” nicotine. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Jessie Hellmann of Modern Healthcare join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
KHN’s ‘What the Health?’: It’s Health Costs, Stupid (2022 Edition)
As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nation’s mental health crisis and what can be done about it.
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
Don’t Nurse That Moscow Mule — It Could Be a Health Hazard
Researchers in Montana have found that unsafe levels of copper can leach into the cocktail in less than half an hour.
Cuidado con este cóctel, puede ser peligroso para la salud
El Moscow Mule se toma en una jarra de cobre, lo que lo vuelve fascinante, y tal vez peligroso.
KHN’s ‘What the Health?’: FDA Takes Center Stage
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of “PDUFA” also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimer’s disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.